全文获取类型
收费全文 | 167260篇 |
免费 | 66354篇 |
国内免费 | 1095篇 |
专业分类
耳鼻咽喉 | 3364篇 |
儿科学 | 6523篇 |
妇产科学 | 2760篇 |
基础医学 | 18371篇 |
口腔科学 | 9728篇 |
临床医学 | 35360篇 |
内科学 | 45717篇 |
皮肤病学 | 10237篇 |
神经病学 | 23426篇 |
特种医学 | 5348篇 |
外科学 | 31186篇 |
综合类 | 224篇 |
现状与发展 | 40篇 |
一般理论 | 26篇 |
预防医学 | 16736篇 |
眼科学 | 3225篇 |
药学 | 6745篇 |
中国医学 | 1040篇 |
肿瘤学 | 14653篇 |
出版年
2024年 | 745篇 |
2023年 | 5065篇 |
2022年 | 1185篇 |
2021年 | 4072篇 |
2020年 | 10349篇 |
2019年 | 12791篇 |
2018年 | 15173篇 |
2017年 | 16880篇 |
2016年 | 17848篇 |
2015年 | 17866篇 |
2014年 | 20362篇 |
2013年 | 22686篇 |
2012年 | 7356篇 |
2011年 | 7195篇 |
2010年 | 14661篇 |
2009年 | 13553篇 |
2008年 | 5256篇 |
2007年 | 3311篇 |
2006年 | 4568篇 |
2005年 | 2867篇 |
2004年 | 2271篇 |
2003年 | 1948篇 |
2002年 | 1962篇 |
2001年 | 2855篇 |
2000年 | 2097篇 |
1999年 | 2202篇 |
1998年 | 2161篇 |
1997年 | 1980篇 |
1996年 | 2025篇 |
1995年 | 1758篇 |
1994年 | 1160篇 |
1993年 | 958篇 |
1992年 | 935篇 |
1991年 | 825篇 |
1990年 | 672篇 |
1989年 | 670篇 |
1988年 | 611篇 |
1987年 | 504篇 |
1986年 | 468篇 |
1985年 | 374篇 |
1984年 | 316篇 |
1983年 | 343篇 |
1982年 | 252篇 |
1981年 | 234篇 |
1980年 | 137篇 |
1979年 | 120篇 |
1978年 | 168篇 |
1977年 | 152篇 |
1976年 | 116篇 |
1974年 | 108篇 |
排序方式: 共有10000条查询结果,搜索用时 15 毫秒
1.
Objective
The aim of the study was to estimate the effect of the state-based reinsurance programs through the section 1332 State Innovation Waivers on health insurance marketplace premiums and insurer participation.Data Source
2015 to 2022 Robert Wood Johnson Foundation Health Insurance Exchange Compare Datasets.Study Design
An event study difference-in-differences (DD) model separately for each year of implementation and a synthetic control method (SCM) are used to estimate year-by-year effects following program implementation.Data Collection/Extraction Methods
Not applicable.Principal Findings
Reinsurance programs were associated with a decline in premiums in the first year of implementation by 10%–13%, 5%–19%, and 11%–17% for bronze, silver, and gold plans (p < 0.05). There is a trend of sustained declines especially for states that implemented their programs in 2019 and 2020. The SCM analyses suggest some effect heterogeneity across states but also premium declines across most states. There is no evidence that reinsurance programs affected insurer participation.Conclusion
State-based reinsurance programs have the potential to improve the affordability of health insurance coverage. However, reinsurance programs do not appear to have had an effect on insurer participation, highlighting the need for policy makers to consider complementary strategies to encourage insurer participation. 相似文献2.
3.
4.
5.
6.
7.
8.
9.
Mette Nissen Tiina‐Mari Ikheimo Jukka Huttunen Ville Leinonen Henna‐Kaisa Jyrkknen Mikael von und zu Fraunberg 《Neuromodulation》2021,24(1):102-111
ObjectiveSpinal cord stimulation (SCS) is an effective treatment in failed back surgery syndrome (FBSS). We studied the effect of preimplantation opioid use on SCS outcome and the effect of SCS on opioid use during a two-year follow-up period.Materials and methodsThe study cohort included 211 consecutive FBSS patients who underwent an SCS trial from January 1997 to March 2014. Participants were divided into groups, which were as follows: 1) SCS trial only (n = 47), 2) successful SCS (implanted and in use throughout the two-year follow-up period, n = 131), and 3) unsuccessful SCS (implanted but later explanted or revised due to inadequate pain relief, n = 29). Patients who underwent explantation for other reasons (n = 4) were excluded. Opioid purchase data from January 1995 to March 2016 were retrieved from national registries.ResultsHigher preimplantation opioid doses associated with unsuccessful SCS (ROC: AUC = 0.66, p = 0.009), with 35 morphine milligram equivalents (MME)/day as the optimal cutoff value. All opioids were discontinued in 23% of patients with successful SCS, but in none of the patients with unsuccessful SCS (p = 0.004). Strong opioids were discontinued in 39% of patients with successful SCS, but in none of the patients with unsuccessful SCS (p = 0.04). Mean opioid dose escalated from 18 ± 4 MME/day to 36 ± 6 MME/day with successful SCS and from 22 ± 8 MME/day to 82 ± 21 MME/day with unsuccessful SCS (p < 0.001).ConclusionsHigher preimplantation opioid doses were associated with SCS failure, suggesting the need for opioid tapering before implantation. With continuous SCS therapy and no explantation or revision due to inadequate pain relief, 39% of FBSS patients discontinued strong opioids, and 23% discontinued all opioids. This indicates that SCS should be considered before detrimental dose escalation. 相似文献